Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Square Power Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 3 examiners across 2 art units, creating both examiner coordination and some art-unit distribution.
KETCHAM, KAREN A is the busiest examiner, with 1 pending action. Counsel should manage consistent portfolio positions while tailoring responses across the three examiner assignments and two art-unit settings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
| THOMAS, TIMOTHY P | 1 | 26.3% | +38.0% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638871 | REBAMIPIDE FOR USE IN PREVENTION AND TREATMENT OF CROHN'S DISEASE | KETCHAM, KAREN A | 50d overdue |
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | THOMAS, TIMOTHY P | — |
| 17638869 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638871 | REBAMIPIDE FOR USE IN PREVENTION AND TREATMENT OF CROHN'S DISEASE | KETCHAM, KAREN A | 50d overdue |
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | THOMAS, TIMOTHY P | — |
| 17638869 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17638871 | REBAMIPIDE FOR USE IN PREVENTION AND TREATMENT OF CROHN'S DISEASE | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 50d overdue | Pending | Feb 28, 2022 |
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | THOMAS, TIMOTHY P | 1614 | §103 | Final Rejection | — | Pending | Feb 28, 2022 |
| 17638869 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER | LADD, CAROLYN LOUISE | 1622 | §102§103§112Other | Non-Final OA | — | Pending | Feb 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSquare Power Ltd. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Karen A Ketcham has the most, with 1 of Square Power Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
